On Wednesday AcelRx Pharmaceuticals (NASDAQ:ACRX) started its trading session with the price $2.04 and closed at price of $1.91 by scoring -5.91%. Day range of the stock was $1.89 – $2.06. ACRX stock traded with total volume of 1859489 shares while the average trading capacity remained 677234 shares. Earnings per share was $-0.81. ACRX has total market capitalization of $151721916.
On Nov. 6, 2019, AcelRx Pharmaceuticals (NASDAQ:ACRX) a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, declared its third quarter 2019 financial results.
Achieving 125 REMS-certified facilities two months ahead of our year-end goal demonstrates healthcare providers’ increasing interest in DSUVIA, said Vince Angotti, Chief Executive Officer of AcelRx. We also expect to achieve our year-end objective of 125 formulary approvals and anticipate expanded use across a variety of healthcare settings as the feedback on DSUVIA® from healthcare professionals continues to be very positive, continued Angotti.
Third Quarter and Recent Highlights
- 130 healthcare facilities are now REMS-certified and able to purchase DSUVIA and 105 formulary approvals have been achieved through October 31, 2019; approximately 60% of REMS certifications and formulary approvals have occurred since the date of the Company’s last earnings call
- AcelRx was selected to present at one of the two plenary sessions of the 2019 Military Health System Research Symposium; the presentation was entitled Pooled Safety Analysis of Patients Who Were Exposed to < 300 mcg vs. ≥300 mcg of Sublingual Sufentanil in a 24 Hour Period for Treatment of Acute Pain
- Pooled dosing and efficacy data from use of the sufentanil sublingual tablet (SST) 30 mcg among multiple demographic subgroups (age, sex, race, and body mass index) was accepted for publication in the Journal of PeriAnesthesia Nursing to aid nurses in understanding the effectiveness and duration of action of SST 30 mcg in the management of moderate-to-severe acute pain across a variety of patient demographics
Julia Brown is a Master’s in Business Administration by education. After completing her post-graduation, Julia jumped the journalism bandwagon as a freelance journalist. Soon after that she landed a job of reporter and has been climbing the news industry ladder ever since to reach the post of editor. As an avid day trader, Julia is a master of technical analysis and writes tirelessly on how stocks are trading. She has extensive knowledge in technical analysis & Finance writing.
Email: [email protected]
Address: 10397 217th Place Northeast, Arlington, WA 98223 USA
Contact number: 425-353-5499